Feeling Collaborative, Merck Inks Three More Deals to Strengthen Portfolio

Collaborations are the backbone of pharmaceutical research. Today, Merck entered into collaborations with three different companies as it looks to expand its oncology offerings. The company continues to assess its vaunted checkpoint inhibitor Keytruda in combination with experimental drugs in different cancer indications.